•  
  •  
  •  
  •  

2025-11-18 21:43:44

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • SIDBI and Bank of Baroda sign MoU to Strengthen Credit Delivery for MSMEs and Startups
  • PDS Limited's Annual Report Wins Gold at LACP 2025 Spotlight Awards
  • Adani Energy Solutions Ltd receives LOI from PFC Consulting Ltd
  • Azad Engineering Ltd signs agreement with Pratt and Whitney Canada Corp
  • Zodiac Energy Limited commissions 3 Solar Power Plants

Keywords Selected:  Pharmaceuticals

Research

  • Kotak Institutional Equities - Pharmaceuticals: IPM pulse - gaining momentum
  • Company Update - P&G Health - ICICI Direct
  • Quant Pick - Cadila Healthcare - ICICI Direct
  • Q2FY22 Result Update - Syngene International - ICICI Direct
  • Syngene International Ltd - Lack of near term triggers - YES Securities
  • Syngene International Ltd - Lower gross margin lead to EBIDTA miss - YES Securities

IPO News

  • Accretion Pharmaceuticals' IPO Opens for subscription today, Price Band set at ₹96-101 per Share
  • Accretion Pharmaceuticals Ltd IPO to open for subscription on May 14, 2025
  • Senores Pharmaceuticals IPO subscribed 13.93 times on Day 2
  • Senores Pharmaceuticals IPO fully subscribed on Day 1
  • Senores Pharmaceuticals gets Sebi nod for IPO

Stock Report

  • Cosmo and Glenmark announce Market Authorization of Winlevi® (clascoterone) 10 mg/g cream for Treatment of Acne in 15 countries in Europe
  • AstraZeneca Pharma India Ltd and Sun Pharma partner to help patients living with Hyperkalaemia in India
  • Relonchem Limited receives Marketing Authorization for its two products
  • Lupin announces closure of Inspection by U.S. FDA at its Nagpur Unit-1 Facility with No Observations
  • Alembic Pharmaceuticals Ltd announces USFDA Final Approval for Diltiazem Hydrochloride Tablets USP, 30 mg, 60 mg, 90 mg, and 120 mg
  • Glenmark Pharmaceuticals Announces Q2FY26 Results
  • Kilitch Drugs' PAT rises by 18% YoY to 10.30 crore in H1 FY26
  • Caplin Point Laboratories Ltd's arm acquires land in Mexico
  • Zydus receives final approval from USFDA for Leuprolide Acetate injection, 14 mg/2.8 mL (1 mg/0.2 mL) multiple-dose vial
  • Aurobindo Pharma gets 9 observations from USFDA for Unit 2 of Eugia Pharma Specialities Ltd
  • USFDA inspects Unit 1 of Divi's Laboratories Limited
  • Lupin Launches Risperidone Long-Acting Injectable with 180-day CGT exclusivity in the U.S.
  • Closure of USFDA inspection at Zydus' oncology injectable manufacturing facility in SEZ1, Ahmedabad
  • SPARC announces consolidation of R&D laboratories and facilities
  • Zydus receives final approval from USFDA for Diroximel Fumarate Delayed-Release Capsules, 231 mg
  • Supriya Lifescience delivers Strong Q2 FY26 Performance with 20.3% YoY Revenue Growth
  • Zydus' Amplitude receives CE mark for its robotic surgical system 'Andy'
  • Lupin Establishes a New Global Standard in Sustainable Pharma with an S&P Global ESG Score of 91
  • Akums Reports Q2 FY26 Results; Strengthens International Presence
  • Alembic Pharmaceuticals Ltd announces USFDA Final Approval Dexlansoprazole Delayed Release Capsules, 30 mg and 60 mg
  • Lupin Receives EIR from U.S. FDA for its Aurangabad (CSN) Facility
  • Lupin Manufacturing Solutions Unveils Dedicated Oncology Block at Vizag, India
  • CARBOGEN AMCIS Holding AG., has Announced Successful Refinancing and Enhancement of their Syndicated Credit Facilities
  • Zydus receives approval from China's NMPA for Venlafaxine Extended-Release Capsules, 75 mg and 150 mg

Industry News

  • NYSE Listed Amneal Pharmaceuticals begins Commercial Operations in India

Latest Post

  • SIDBI and Bank of Baroda sign MoU to Strengthen Credit Delivery for MSMEs and Startups
  • PDS Limited's Annual Report Wins Gold at LACP 2025 Spotlight Awards
  • Adani Energy Solutions Ltd receives LOI from PFC Consulting Ltd
  • Azad Engineering Ltd signs agreement with Pratt and Whitney Canada Corp
  • Zodiac Energy Limited commissions 3 Solar Power Plants


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2024